Multiple Myeloma Stem Cells and Drug Resistance in Myeloma Management

September 27, 2019

Upcoming / RECENT Talks

Multiple Myeloma Stem Cells and Drug Resistance in Myeloma Management

with Dr. William Matsui

Sept 30, 2019, 11 AM ET

RSVP

Multiple myeloma is a heterogenous plasma cell disorder that contains a small fraction of clonogenic stem cells, just like many other cancers. Although the exact nature and biological properties of these cells remain elusive, multiple myeloma stem cells (MMSCs) have pronounced drug resistance and are believed to be the root cause of failure of many myeloma management therapies. We are talking to Dr William Matsui of LIVESTRONG Cancer Institutes to learn about the latest research on multiple myeloma stem cells and their role in novel drug development to treat multiple myeloma.

Panelists

Dr. William Matsui

Gary Petersen

Cynthia Chmielewski

Jack Aiello

Shweta Mishra

Sept 4, 2019, 3 PM ET

LISTEN

Recently, the FDA approved a new cancer drug called Selinexor. This drug has been found to be successful in treating multiple myeloma in patients who have exhausted all other existing treatment options. Selinexor works on a different mechanism compared to other drugs. It enters a cell and targets mechanisms that move molecules into and out of the cell. We are talking to Dr. Dan Vogl, who lead the Phase II studies on Selinexor, on how the drug works, how it should be used, potential side effects and who should consider using it.

Panelists

Dr. Dan T Vogl

Gary Petersen

Jack Aiello

Cynthia Chmielewski

Priya Menon

Sept 3, 2019, 2 PM ET

LISTEN

Nearly all patients with multiple myeloma first develop one of its precursor conditions. People with these conditions do not have any symptoms, and they are told to watch and wait to see if they develop multiple myeloma. Currently, there are no treatments that prevent the progression of myeloma precursor conditions. To overcome this, researchers need to understand changes happening at the molecular level and identify potential targets for treatment. Dr. Irene Ghobrial of Dana Farber Cancer Institute is talking to us about the new PROMISE study, the biggest myeloma screening study ever run to help prevent myeloma before it begins and share how you can join the study and help in research.

Panelists